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Abstract
Background: Chronic obstructive pulmonary disease (COPD) patients may experience an acute exacerbation
(AECOPD) that requires hospitalisation. The length of hospital stay (LHS) has a great economic impact on the
health-care system. Knowing the predictors of prolonged LHS could help to identify possible interventions.
Methods: We performed a prospective study to identify the clinical predictors of prolonged LHS in patients
hospitalised for AECOPD. We divided the study sample by LHS into normal (≤7 days) and prolonged LHS (> 7 days)
groups. Outcomes were the need for non-invasive and invasive mechanical ventilation (NIMV and IMV), intensive
care unit (ICU) admission, and the 3-year mortality.
Results: We enrolled 437 patients, of which 213 and 224 had normal LHS and prolonged LHS, respectively. Patients
with a prolonged LHS had more prior hospitalisations for AECOPD, a worse mMRC (modified Medical Research
Council) dyspnoea score, a higher prevalence of long-term oxygen therapy and a higher rate of congestive heart
disease. During the current admission, this group also tended to require NIMV, IMV and ICU admission and the
mortality risks at 6 months, 1 year and 3 years were higher. In the multivariate regression analysis, an mMRC
dyspnoea score ≥ 2 (odds ratio-OR 2.24; 95% confidence interval-CI 1.34 to 3.74; p = 0.002) and the presence of
acute respiratory acidosis (OR 2.75; 95% CI 1.49 to 5.05; p = 0.001) predicted a prolonged LHS at admission.
Conclusions: The presence of an mMRC ≥2 and acute respiratory acidosis at admission independently increased
the risk of a prolonged LHS for AECOPD.
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Introduction
The recent Global Burden of Disease study reported that
chronic obstructive pulmonary disease (COPD) was a
prevalent cause of death worldwide [1]. Acute exacerbations
of COPD (AECOPD), which are characterised by a
worsening of respiratory signs and symptoms and an in-
creasing of domiciliary therapies [2], may occur during the
clinical course of disease and increase the mortality. Related
to this aspect, some patients need hospitalisation depending
on the severity of the AECOPD [2, 3] and if it prolonged,
this can increase the costs of managing the disease [4].
The length of hospital stay (LHS) for an AECOPD is
related to several factors. These include age [5], disease
severity [5, 6], the presence of comorbidities [7, 8], high
carbon dioxide partial pressures (PCO2) [7], the need of
mechanical ventilation [6] or an intensive care unit
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(ICU) [9], a low serum albumin level [7], the dyspnoea
perception [10] and the respiratory rate [8]. Other vari-
ables, such as admissions at the weekend [8] and social
factors [11], have also been considered relevant. How-
ever, three aspects need to be highlighted in these stud-
ies. First, some of them were based on audit data [6],
medical records [7] or retrospective analysis [10, 11] and
not from prospective observational data. Second, differ-
ent thresholds have been used to define a prolonged
LHS (e.g., 4 days [8], 8 days [10], 9 days [9], or 11 days
[7]), despite evidences that the normal LHS required for
AECOPD should be 6 or 7 days [12], based on the oc-
currence and timing of complications. Third, no studies
have evaluated several clinical variables all together at
the time and before hospital admission.
In this prospective study, we aimed to identify the
clinical variables at the time and before hospital admis-
sion that increase the risk of prolonged LHS (defined as
> 7 days) in patients hospitalised for AECOPD. Due to
the impact of LHS on clinical, social and economic out-
comes, we believe that identifying the predictors of pro-
longed LHS could help clinicians to develop targeted
interventions for these patients.
Methods
Study cohort
We performed a prospective study at the Hospital Clinic
of Barcelona, Spain, over a 7-years period from May 2009
to May 2016. We systematically enrolled all patients ad-
mitted for an AECOPD to our pneumology department.
Included patients had to meet the diagnostic criteria for
COPD, as set out by the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) [2]. For the diagnosis, we
considered spirometry measurements in the stable phase
at least six months before hospital admission and patients
were considered positive for smoking if they had a history
of 20 pack-years [2]. According to the GOLD document
[2], AECOPD was defined as a recent worsening of re-
spiratory symptoms that required a change in domiciliary
therapy, with the need for hospitalisation based on the se-
verity of AECOPD and the presence of indicators [2]. Ac-
cording to the literature [12] and related to the median
value of the LHS in our study sample that was 7 days, pa-
tients with an AECOPD were divided into a group with
normal LHS (≤7 days) and a group with prolonged LHS
(> 7 days). We excluded patients with a documented his-
tory of other concomitant chronic respiratory diseases
(e.g., asthma, cystic fibrosis or interstitial lung disease) or
those in whom a community-acquired pneumonia or
acute heart failure were identified by clinical signs, chest
X-ray or computed tomography at admission.
The hospital’s ethics committee approved the study
protocol (CEIC 2008/4106), and we conducted the study
according to the requirements of Good Clinical Practice
and the declaration of Helsinki, including later revisions.
All participants gave signed informed consent.
Microbiological sample collection
On the first day of hospitalisation, we collected sputum
from a spontaneous cough sample; if adequate (a count of
> 25 leukocytes and < 10 epithelial cells per field) it was
processed by Gram staining and culture. In patients who
did not provide a spontaneous sputum sample, we obtained
an induced sputum production by inhalation of a 5% hyper-
tonic saline solution delivered via nebuliser for 5 to 10min.
General measurements
We recorded data about demographic variables, body
mass index, smoking habit (current or former, including
the number of pack-years), number of comorbidities
(using the Charlson index), prevalence of ischaemic heart
disease and diabetes, dyspnoea grade (measured by the
modified Medical Research Council [mMRC] scale), dis-
ease severity (using the COPD severity score [COPD-SS]
questionnaire) and use of long-term oxygen therapy
(LTOT). We also collected data about the season of occur-
rence of AECOPD, the characteristics and numbers of
AECOPD events in the last year, and details of home care
medications (short-acting β2 agonists, long-acting β2 ago-
nists, anticholinergics and inhaled corticosteroids).
We recorded body temperature, respiratory rate, heart
rate and blood pressure (systolic and diastolic) at admis-
sion. In addition, we recorded gas analysis (pH, partial
arterial carbon dioxide pressure [PaCO2], the ratio of
partial arterial oxygen pressure to the fraction of in-
spired oxygen [PaO2/FiO2], serum bicarbonate [HCO3
−],
and base excess [BE]), systemic response (i.e., leukocytes,
haematocrit, haemoglobin, C-reactive protein [CRP],
glucose and creatinine) as both at admission and at day
3. Finally, we recorded how many patients used systemic
corticosteroids and antibiotics, the antibiotic classes and
the duration of antibiotic treatment.
Outcomes
Clinical progression was evaluated based on the need for
non-invasive and invasive mechanical ventilation (NIMV
and IMV, respectively) and for admission to ICU. Data
on prognosis (i.e., cumulative number of all-cause deaths
and estimated time to death) were recorded during
follow-up at 30 days, 6 months, 1 year and 3 years. The
date of death was identified using centralised registries.
Statistical analysis
We reported categorical variables as numbers and per-
centages and we reported continuous variables as means
± standard deviations or as medians (1st quartile; 3rd
quartile) for normal and non-normal distributions,
respectively. Categorical variables were compared using
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the X [2] test or the Fisher exact test, while continuous
variables with the t test or the non-parametric
Mann-Whitney test, as appropriate. All statistical ana-
lyses were performed using IBM SPSS, version 25.0
(IBM Corp., Armonk, NY, USA). A p-value of < 0.05 was
considered statistically significant.
Univariate and multivariate regression logistic models
were performed with the stepwise method to predict the
probability of a prolonged LHS (the dependent variable).
The independent variables in the univariate analyses were
as follows: mMRC dyspnoea score (≥ 2); GOLD 2017
stages A, B, C or D; number of previous AECOPD epi-
sodes requiring hospitalisation (≥1); use of LTOT; symp-
tom duration before admission (≥7 days); pre-admission
therapy, including antibiotic use within 3months, salbuta-
mol use within two weeks and ipratropium bromide use
within two weeks; the COPD-SS (≥15); the presence of a
comorbidity such as ischaemic or congestive heart disease,
diabetes or chronic kidney failure); the presence of acute
respiratory acidosis (pH < 7.35), at admission and day 3,
hypercapnia (PCO2 > 45mmHg), acute severe hypoxemia
(PaO2/FiO2 ratio < 200) and renal bicarbonate retention
(HCO3 > 30mmol/L); NIMV use; a positive sputum cul-
ture for Pseudomonas aeruginosa in the previous year or
during hospitalisation, a microorganism resistant to con-
ventional treatment (MRCT) or Streptococcus pneumo-
niae; antibiotic use during hospitalisation. Variables that
showed a significant result (p < 0.1) were included in the
subsequent multivariate regression stepwise model. To
detect collinearity, we calculated the r coefficient of two
variables and for those highly correlated (r > | ± 0.30|) the
variable with the largest variance was excluded from the
multivariate analysis [13]. Odds ratios (ORs) and 95% con-
fidence intervals (CI) were then calculated.
Time-to-event variables were analysed by Kaplan–Meier
survival curves and the Gehan–Breslow–Wilcoxon test
was applied to emphasise early differences [14]. Patients
lost to follow-up were censored in the survival analysis.
Cox proportional hazard regression models were used
to report the mortality at 30 days, 6 months, 1 year
and 3 years [15], and we calculated the hazard ratios
and 95% CIs.
Results
General data on study cohort
Over the 7-year study period, we enrolled 449 patients
admitted for an AECOPD; of these, 12 died during hos-
pitalisation and so excluded. Among the 437 remaining
patients, 213 had a normal LHS and 224 had a pro-
longed LHS. In comparison to the normal LHS group,
the prolonged LHS group had higher rates of GOLD D
stage, LTOT, associated congestive heart disease and
prior hospitalisations for AECOPD. The prolonged LHS
group had also worse dyspnoea perception, longer symp-
tom duration before admission and greater requirement
of salbutamol and ipratropium in the two weeks before
admission. Figure 1 shows the flow diagram for the
study and Table 1 shows the baseline characteristics.
Fig. 1 Study flow chart
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Table 1 Baseline characteristics of patients by the length of hospital stay
Variables Normal LHS (≤ 7 days) (n = 213) Prolonged LHS (> 7 days) (n = 224) p value
Domiciliary medications
Age, years 73 [64.5; 78] 72 [64; 78] 0.857
Male, % 82 80 0.637
BMI, kg/m2 27 [24.2; 29.4] 27.6 [23.4; 31.5] 0.486
Smoking habit: Current/Former, % 41/59 39/61 0.598
Pack/year 50 [40; 80] 60 [40; 80] 0.797
FEV1, % predicted 44 [33; 63] 42 [30; 58] 0.126
FEV1/FVC 49.5 [38.7; 62] 49 [36; 62.7] 0.823
GOLD 2017 stages: A/B/C/D, % 32/32/15/21 18/39/12/31 0.015
LTOT, % 22 32 0.013
mMRC dyspnoea grade 2 [1; 3] 2 [1; 4] 0.001
COPD-SS severity questionnaire 13 [8; 18] 14 [9; 19] 0.108
Charlson index 2 [1; 3] 2 [1; 3] 0.750
Ischaemic heart disease, % 11 9 0.501
Congestive heart disease, % 9 18 0.008
Diabetes, % 21 23 0.618
Chronic kidney failure, % 4 7 0.257
Season of admission: Winter/Spring/Summer/Autumn, % 40/14/29/17 45/16/25/14 0.508
Period of admission: years 2009–2011/2012–2104/2015–2017, % 61/31/8 58/30/12 0.463
Previous AECOPDa 0 [0; 1] 0 [0; 2] 0.286
Patients with ≥2 previous AECOPDa, % 24 27 0.501
Previous AECOPD requiring hospitalisationa 0 [0; 1] 0 [0; 1] 0.030
Patients with ≥1 previous AECOPD requiring hospitalisationa, % 28 37 0.029
Onset of symptoms until admission, days 4 [2; 7] 5 [3; 7.75] 0.035
Use of antibiotics previous admission
In a period of one week before, % 24 23 0.924
Days of treatment 7 [3; 10] 6 [3; 7] 0.625
Penicillins/Fluoroquinolones/Macrolides/Cephalosporins/Others, % 30/48/11/2/9 24/40/18/11/7 0.248
In a period of three months before, % 40 53 0.044
Penicillins/Fluoroquinolones/Macrolides/Cephalosporins/Others, % 23/63/5/0/9 34/45/10/8/3 0.149
Use of other drugs in a period of two weeks before admission
Systemic corticosteroids, % 12 13 0.867
Salbutamol, % 4 14 0.001
Ipratropium bromide, % 5 13 0.005
Domiciliary medications
Salbutamol only, % 3 3 0.922
Anticholinergic only, % 5 5 0.819
LABA + Anticholinergic, % 2 1 > 0.999
LABA + ICS, % 3 2 > 0.999
Anticholinergic + ICS, % 2 1 > 0.999
LABA + Anticholinergic + ICS, % 36 37 0.828
Data are shown as number of patients (percentage) or medians [1st quartile; 3rd quartile], unless otherwise stated. Percentages are calculated for
non-missing data
LABAs include salmeterol, formoterol and indacaterol; Anticholinergics include ipratropium and tiotropium; and ICS include budesonide and fluticasone
aPrevious AECOPD were considered if occurring in a period of the preceding year
Abbreviations: BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; COPD-SS, COPD severity score questionnaire; FEV1, forced
expiratory volume in the 1st second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled
corticosteroids; LABA, long-acting β2 agonist; LHS, length of hospital stay; LTOT, long-term oxygen therapy; mMRC, modified Medical Research Council
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Clinical, laboratory and microbiological variables
Blood gas analysis at admission (Fig. 2) revealed
worse values in the prolonged LHS group than in the
normal LHS groups for pH (median [1st quartile; 3rd
quartile] 7.37 [7.32; 7.42] versus 7.41 [7.36; 7.44]),
PaCO2 (51.7 mmHg [40.3; 66] versus 44.3 mmHg
[37.4; 53]), PaO2/FiO2 (251.9 [204.2; 306.6] versus
272.3 [231.6; 315.7]), HCO3− (28.9 mmol/L [24.9; 34]
versus 26.7 mmol/L [24.4; 30.3]). At day 3, different
levels for pH and PaCO2 were confirmed in the study
groups. In the prolonged LHS group, fluoroquinolone
use was lower and cephalosporin use was higher
when compared with the normal LHS group. All
other clinical and laboratory variables were similar
between the study groups (Table 2).
Table 3 summarises the results of microbiological
testing. In the year before hospitalisation, the preva-
lence of patients with positive cultures, ≥1 pathogens
or positive samples for P. aeruginosa or MRCT was
higher in the prolonged LHS group compared with
the normal LHS group. In the samples collected
during hospitalisation, P. aeruginosa and MRCT
occurred more frequently in the prolonged LHS
group, while S. pneumoniae occurred less frequently.
Finally, the prevalence rates of P. aeruginosa and
MRCT colonisation were higher in the prolonged
LHS group (100 and 90% of cases, respectively).
Study outcomes
All the outcomes (i.e., NIMV use, IMV use, ICU admis-
sion, and mortality) were worse in the prolonged LHS
group compared with the normal LHS group (Table 4).
Similarly, the survival time and the Kaplan–Meier curves
in the three follow-up periods (i.e., 6 months, 1 year and 3
years) were significantly different between groups, with
worse prognosis for patients with prolonged LHS (Fig. 3).
Prediction analyses
Several clinical variables predicted LHS in the univariate
analyses (Table 5). The following were significant predic-
tors of an increased risk of a prolonged LHS: mMRC dys-
pnoea score ≥ 2, GOLD stage B and D, ≥1 previous
AECOPD requiring hospitalisation, LTOT use, symptom
duration ≥7 days before admission, drug use before admis-
sion (antibiotics three months before and salbutamol and
ipratropium two weeks before), COPD-SS questionnaire
≥15, the presence of a congestive heart disease, acute re-
spiratory acidosis or severe hypoxemia at admission, hy-
percapnia at admission and day 3, renal bicarbonate
retention at admission, the need for NIMV, the presence
of P. aeruginosa or of MRCT colonisation and the use of
cephalosporins during hospitalisation. The presence of S.
pneumonia and the use of fluoroquinolones were associ-
ated with a reduced risk of a prolonged LHS.
Fig. 2 Blood gas analysis on admission and day 3. White and grey represent the AECOPD patients with normal LHS and prolonged LHS,
respectively. Abbreviations: PaCO2, partial pressure of arterial carbon dioxide; PaO2/FiO2, ratio of partial pressure of arterial oxygen to the fraction
of inspired oxygen; HCO3
−, serum bicarbonate; BE, base excess
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In the multivariate and multivariate adjusted analyses,
an mMRC dyspnoea score ≥ 2 and the presence of acute
respiratory acidosis at admission were independently
confirmed as predictors of a prolonged LHS.
Readmissions and LHS
In comparison with the normal LHS group, the prolonged
LHS group had higher probability of readmission, espe-
cially for one readmission and for the period ≤30 days after
discharge (Fig. 4). The time to first readmission was lower
in the prolonged LHS group compared with the normal
LHS group (47 days [19; 167] versus 95 days [38; 221].
Supplementary analysis not shown
We repeated all predictive and prognosis analyses after
excluding patients admitted to ICU during hospitalisa-
tion (n = 52) or who required IMV (n = 17) [16] or who
required facilities at discharge (n = 25) and the results
were equal to those reported for the full cohort. There-
fore, we have excluded this detail from the main report.
Table 2 Clinical and laboratory variables
Variables Normal LHS (≤ 7 days) (n = 213) Prolonged LHS (> 7 days) (n = 224) p value
Respiratory rate, b/min 24 [20; 28] 24 [20; 28] 0.482
Heart rate, b/min 91.5 [83; 102.5] 95 [80; 108] 0.293
Body temperature, °C 36.4 [35.9; 37] 36.3 [36; 36.8] 0.569
SBP, mmHg 140 [120; 155] 135.5 [124; 156] 0.719
DBP, mmHg 75 [68; 86] 76 [68; 87] 0.895
Laboratory variables at admission
Leucocytes, 109/l 10.1 [7.9; 14] 10.1 [7.7; 13.6] 0.464
Haematocrit, % 43 [39; 47] 43 [40; 47] 0.425
Haemoglobin, g/L 138 [125; 151] 140 [127; 153] 0.738
C-reactive protein, mg/dL 4.1 [1.3; 10.1] 3.6 [1.1; 9.7] 0.412
Glucose, mg/dL 123 [108; 152.7] 126 [107.7; 166] 0.485
Creatinine, mg/dL 0.9 [0.8; 1.1] 0.9 [0.7; 1.1] 0.041
Laboratory variables at day 3
Leucocytes, 109/l 10.6 [8.3; 13.4] 10.7 [8.1; 13] 0.922
Haematocrit, % 41 [38; 44] 41 [37; 45] 0.685
Haemoglobin, g/L 131 [119; 143] 131 [118; 143] 0.436
C-reactive protein, mg/dL 1.4 [0.5; 4.1] 0.9 [0.3; 2.9] 0.161
Glucose, mg/dL 116 [96; 153] 123 [100.5; 161] 0.096
Creatinine, mg/dL 0.9 [0.7; 1.2] 0.8 [0.7; 1] 0.027
Treatments during hospitalisation
Systemic corticosteroids, % 91 92 0.631
Antibiotics, % 84 88 0.304
Number of antibiotics used, 0/1/≥2, % 16/64/20 12/64/24 0.383
Duration of antibiotic treatment, days 7 [5; 10] 7 [6; 10] 0.375
Penicillins, % 16 19 0.498
Fluoroquinolones, % 57 45 0.023
Macrolides, % 2 2 > 0.999
Cephalosporins, % 1 5 0.035
Carbapenems, % 0 1 0.501
Data are shown as number of patients (percentage) or medians [1st quartile; 3rd quartile], unless otherwise stated. Percentages are calculated for
non-missing data
Systemic corticosteroids include methylprednisolone; penicillins include amoxicillin and amoxicillin/clavulanate; fluoroquinolones include ciprofloxacin,
moxifloxacin and levofloxacin; macrolides include azithromycin and clarithromycin; cephalosporins include ceftriaxone, cefotaxime, cefuroxime and cefepime; and
carbapenems include meropenem
Abbreviations: DBP and SBP indicate diastolic and systolic blood pressure, respectively; LHS, length of hospital stay
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Discussion
This prospective observational study of hospitalised pa-
tients for AECOPD allows us to make three important
conclusions. First, we showed that a LHS of ≥7 days
identified a typology of severe AECOPD with common
chronic baseline characteristics, including worse disease
staging, worse symptom perception, LTOT use and col-
onisation by P. aeruginosa or MRCT. These patients
were also at high risk of early readmission to hospital.
Second, patients with a prolonged LHS had a worse
prognosis until at least 3 years after discharge. Third, at
hospital admission, a severe perception of dyspnoea
(mMRC scale ≥2) and the presence of acute respiratory
acidosis significantly increased the risk of a prolonged
LHS. These three aspects of a presentation could help us
focusing which patients are at risk of prolonged LHS
and ultimately, providing tailored interventions [17–19].
Regarding the threshold for defining a prolonged LHS,
we have already noted the existing variations [7–10]. As
outlined, we used the threshold of 7 days in line with the
time when complications typically develop in an
AECOPD [12]. Overall, the baseline characteristics of
Table 3 Microbiological variables
Sputum sample collected in the
previous year the hospitalisation















Patients with positive cultures 63 33 67 0.008 91 35 43 0.179
Number of pathogens: 0 373 51 49 0.031 346 51 49 0.138
1 43 33 67 89 39 61
≥ 2 20 35 65 2 50 50
Pseudomonas aeruginosa 16 13 87 0.041 25 12 88 0.001
Pseudomonas aeruginosa colonisationc – – – – 9 0 100 0.002
Haemophilus influenzae 5 60 40 0.323 16 31 69 0.454
Streptococcus pneumoniae 7 43 57 0.677 18 61 39 0.037
Streptococcus spp. 5 20 80 0.657 – – – –
Staphylococcus spp. 4 50 50 0.595 7 29 71 0.699
Pasteurella – – – – 2 50 50 > 0.999
Moraxella catarrhalis 3 67 33 0.256 3 100 0 0.059
Candida spp. – – – – 2 50 50 > 0.999
Aspergillus – – – – 2 50 50 > 0.999
Serratia – – – – 1 0 100 > 0.999
Escherichia coli 1 0 100 > 0.999 – – – –
Mycobacterium no-TBC – – – – 1 100 0 0.396
Polymicrobial 20 35 65 0.848 8 50 50 0.708
Classification according to the conventional
treatmentb: MSCT
31 45 55 0.026 51 51 49 0.014
MRCT 20 15 85 30 23 77
MRCT colonisationc – – – – 10 10 90 0.009
Influenza B virus – – – – 2 50 50 > 0.999
Respiratory syncytial virus – – – – 7 43 57 > 0.999
Rhinovirus – – – – 7 29 71 0.450
Parainfluenza virus type 1 – – – – 3 67 33 0.615
Parainfluenza virus type 3 – – – – 3 0 100 0.499
Parainfluenza virus type 4 – – – – 1 100 0 0.487
aData reported as percentage related to number of cases for each of sputum sample. bPatients considered MSCT (for aminopenicillin with clavulanic acid, a
macrolide or a tetracycline) or MRCT (Pseudomonas aeruginosa, MRSA, Stenotrophomonas maltophilia, Enterobacteriaceae producer of extended spectrum of beta
lactamase and Acinetobacter baumannii) [2]. cColonisation was defined for a positive culture for the same microorganism in the sputum sample collected in the
previous year and during hospitalisation. p value was calculated versus patients with a negative sample
Abbreviations: LHS, length hospital stay; MRSA, methicillin-resistant Staphylococcus aureus; MSCT and MRCT, microorganisms sensible and resistant to
conventional treatment
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our AECOPD cohort were comparable to those of other
studies [6, 7, 20], but we also considered variables not
previously reported in this field. These included the
symptom duration before admission and the use of anti-
biotics and the received therapy in both the short- and
the long-term before hospitalisation. These allow us to
state that prolonged LHS was related to increased treat-
ment requirements in the period just prior to admission;
for example, this group had higher rates of antibiotic use
in the 3 months before the admission and higher rates of
as-needed bronchodilator use in the 2 months before the
admission (Table 1).
Concerning to the microbiological results, our data sup-
port those showing a close relationship between bacterial
infection and the LHS [21]. Although coinfection with
bacteria and viruses may also prolong hospitalisation [21],
we did not find a statistically significant association. By
contrast, we showed that P. aeruginosa [22] and MRCT
[23] are clinical factors that influence outcomes and pro-
long hospitalisation. Consistent with these microbiological
findings and data about the impact of treatment failure
[24], patients treated with fluoroquinolones during hospi-
talisation had a lower risk of a prolonged hospitalisation
(Table 5). Finally, we believe that it was noteworthy that
colonisation with P. aeruginosa or MRCT (Tables 3 and 5)
played a role in prolonging the LHS.
We showed, for the first time, that patients with a pro-
longed LHS have a higher risk of mortality until at least
3 years after discharge. This is in line with research that
looked at the need for intubation and IMV with regards
the LHS [16]. Given this close relationship between ICU
admission and prolonged LHS, we repeated all our ana-
lyses after excluding patients transferred to ICU, but ob-
tained similar results. The high prevalence of early
readmissions (≤ 30 days the discharge) in the prolonged
LHS group confirmed the results of previous research
[25]. That said, it should be noted that the previous re-
search considered the threshold for a prolonged LHS to
be > 4 days, which is probably too short to cure a severe
AECOPD. Nevertheless, we contend that a prolonged
LHS reflects a severe and chronic underlying disease,
resulting in a subgroup with a worse prognosis [26, 27].
Predictors of long hospital stay
Univariate analysis indicated that several variables pre-
dicted a prolonged LHS and this could be useful to de-
velop integrated interventions. However, the multivariate
analysis, adjusted for anthropometric characteristics,
Table 4 Study outcomes
Variables Normal LHS (≤ 7 days) (n = 213) Prolonged LHS (> 7 days) (n = 224) p value
NIMV, % 11 31 < 0.001
IMV, % 0 7 < 0.001
ICU admission, % 5 19 < 0.001
Mortality at 6-months, % 4 14 < 0.001
Survival time 176.3 [173.8 to 178.8] 168.5 [164.3 to 172.7] 0.001
Cumulative mortality at 1-year, % 11 25 < 0.001
Survival time 342.5 [334.4 to 350.5] 313.6 [301.1 to 326.2] < 0.001
Cumulative mortality at 3-years, % 37 48 0.036
Survival time 904.6 [862.3 to 946.8] 783.8 [730.6 to 837.1] 0.007
Data are shown as number of patients (percentage) and calculated for non-missing data
Survival time was calculated as mean [95% confidence interval] and reported as days
Abbreviations: NIMV and IMV indicate non-invasive and invasive mechanical ventilation, respectively; ICU, intensive care unit
Fig. 3 Kaplan-Meier survival curves at 6 months, 1 year and 3 years by length of hospitalisation
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showed that only dyspnoea perception and acute
respiratory acidosis significantly increase the risk of a
prolonged LHS. These clinical conditions have both
been associated with prolonged LHS [6, 7, 9, 20],
though the respective researches used different mea-
sures of respiratory acidosis, such as dyspnoea [9, 20],
hypercapnia [7] or the need for NIMV [6]. Moreover,
these data were not prospectively obtained [6, 7] and
they used different study designs [6, 7, 10], methodolo-
gies [6, 7, 10] and settings [8, 9].
Only the study of Tsimogianni et al. [10] considered
the mMRC and body mass index as independent
predictors of a prolonged LHS, but they used retro-
spective analysis and a threshold of > 8 days to indicate
a prolonged LHS [10]. In the same cohort, our results
integrate a subjective patient-reported variable (dys-
pnoea by mMRC) with an objectively measured vari-
able (pH by blood gas analysis), which may provide an
opportunity to develop tailored interventions. It is true
that the presence of acute respiratory acidosis corre-
lates to the need for NIMV and independently of the
need for ICU admission or IMV it will require more
time for cure (e.g., adapting to mechanical ventilation
and recovery from acute respiratory failure). However,
Table 5 Univariate and multivariate regression analyses predicting the probability to have a prolonged hospitalisation
Variable Univariate Multivariate
OR 95% CI p value OR 95% CI p
mMRC dyspnoea score (≥ 2) 2.07 1.29 to 3.32 0.002 2.24 (2.76) 1.34 to 3.74 (1.54 to 4.92) 0.002 (0.001)
GOLD 2017 stages: Stage A 1.00
Stage B 2.24 1.22 to 4.08 0.009 – – –
Stage C 1.48 0.68 to 3.20 0.322 – – –
Stage D 2.60 1.35 to 4.98 0.004 – – –
No. of previous AECOPD requiring hospitalisation (≥ 1) 1.57 1.05 to 2.35 0.030 – – –
Use of LTOT 1.72 1.12 to 2.64 0.014 – – –
Onset of symptoms until admission (≥ 7 days) 1.49 0.99 to 2.42 0.053 – – –
Use of antibiotics three months before admission 1.72 1.01 to 2.93 0.044
Use of salbutamol two weeks before admission 3.44 1.59 to 7.43 0.002 – – –
Use of ipratropium two weeks before admission 2.84 1.34 to 6.01 0.006 – – –
COPD-SS (≥ 15 score) 1.39 0.94 to 2.05 0.095 – – –
Presence of congestive heart disease 2.14 1.21 to 3.79 0.009 – – –
Acute respiratory acidosis at admissiona 2.41 1.50 to 3.88 < 0.001 2.75 (2.68) 1.49 to 5.05 (1.34 to 5.38) 0.001 (0.005)
Hypercapnia at admissionb 1.90 1.26 to 2.87 0.002 – – –
Hypercapnia at day 3b 2.05 0.97 to 4.32 0.061 – – –
Acute severe hypoxemia at admissioncd 2.32 1.14 to 4.73 0.020
Renal bicarbonate retention at admissione 1.84 1.21 to 2.80 0.004
Need for NIMV 3.53 2.12 to 5.88 < 0.001
Pseudomonas aeruginosa in the sputum sample
of the previous yearf
4.75 0.96 to 23.34 0.055
MRCT colonisationf 9.84 1.23 to 78.59 0.031
Pseudomonas aeruginosa in the sputum sample
during hospitalisationf
7.33 2.00 to 26.88 0.003
Streptococcus pneumoniae in the sputum sample
during hospitalisationf
0.33 0.11 to 0.96 0.042
Use of cephalosporins during hospitalisation 4.54 0.98 to 21.06 0.053
Use of fluoroquinolones during hospitalisation 0.61 0.40 to 0.93 0.023
In the univariate model the statistical significance considers a p value < 0.1. Data in parentheses report the multivariate model adjusted for anthropometric
variables. Hosmer and Lemeshow Test p = 0.956 and p = 0.642 in the multivariate and multivariate adjusted model, respectively
aAcute respiratory acidosis: pH < 7.35; bHypercapnia: PCO2 > 45 mmHg;
cAcute severe hypoxemia: PaO2/FiO2 ratio < 200;
dAnalysis excluding patients with LTOT;
eRenal bicarbonate retention: HCO3 > 30 mmol/L;
fDefinition and criteria are reported in Table 3
Abbreviations: COPD, chronic obstructive pulmonary disease; COPD-SS, COPD severity score questionnaire; GOLD, global initiative for chronic obstructive lung
disease; HCO3
−, serum bicarbonate; LTOT, long-term oxygen therapy; mMRC indicate modified Medical Research Council; MRCT, microorganisms resistant to
conventional treatment; NIMV, non-invasive mechanical ventilation; PaCO2, partial arterial carbon dioxide pressure; PaO2/FiO2, ratio of partial arterial oxygen
pressure to the fraction of inspired oxygen
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we believe that there is also a need to focus on the pa-
tient’s self-report of dyspnoea given its accuracy as a
predictor of the LHS. In patients with COPD, the
mMRC questionnaire is a simple measure of dyspnoea
perception [28, 29] that is adequate for symptom as-
sessment, relating to both health status [30] and exer-
cise tolerance [31]. Moreover, the mMRC has been
shown to predict mortality [32]. Our findings confirm
the role of mMRC in the prediction of patients with a
prolonged LHS.
Strength and limitation
The main strengths of this observational study were the
choice of a definition of prolonged LHS based on
clinical experience, the inclusion of many clinical
variables, and the long follow-up period to 3 years.
However, there were some important limitations. First,
although we collected data for more than 400 patients,
these derived from a single centre in Spain; therefore, a
multicentre study is needed to confirm our results.
Second, the research was based on clinical experience
by pneumologists and limited to hospital care, so inte-
grations with social variables or economic resources
may have been lacking [11]. Finally, related to the po-
tentially effect of in-hospital therapy on LHS, our find-
ings are produced by an observational study and then
with difficult comparable. A randomized trial in which
all patients receive the same therapy may be useful.
Fig. 4 The readmission rates were evaluated for the periods ≤30 days and > 30 days from discharge. White and grey represent the AECOPD
patients with normal LHS and prolonged LHS, respectively
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Conclusions
In conclusion, an mMRC score of ≥2 and the presence
of respiratory acidosis at admission predict hospitalisa-
tion for > 7 days in patients with AECOPD. Moreover,
hospitalisation for > 7 days is a marker of severity that
affects major prognostic outcomes. These findings could
be clinically relevant by helping to identify at-risk pa-
tients when they present to hospital. If these predictors
can be shown to be modifiable, which they potentially
are, we may be able to offer tailored interventions both
before and during admission.
Abbreviations
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protein; FEV1: Forced expiratory volume in the 1st second; HCO3
−: Serum
bicarbonate; ICS: Inhaled steroids; ICU: Intensive care unit; IMV: Invasive
mechanical ventilation; LHS: Length of hospital stay; LTOT: Long-term
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invasive mechanical ventilation; PaCO2: Partial arterial carbon dioxide
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